Hemogenyx Pharmaceuticals Plc (LON:HEMO – Get Free Report) hit a new 52-week high on Friday . The company traded as high as GBX 410 ($5.20) and last traded at GBX 400.50 ($5.08), with a volume of 102058 shares traded. The stock had previously closed at GBX 1.08 ($0.01).
Hemogenyx Pharmaceuticals Stock Performance
The business has a 50-day moving average of GBX 1.24 and a two-hundred day moving average of GBX 1.33. The company has a debt-to-equity ratio of 92.09, a current ratio of 4.38 and a quick ratio of 6.72. The company has a market cap of £5.61 billion, a P/E ratio of -107.50 and a beta of 3.14.
Hemogenyx Pharmaceuticals Company Profile
Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.
Further Reading
- Five stocks we like better than Hemogenyx Pharmaceuticals
- What is MarketRank™? How to Use it
- WallStreetBets: How a Reddit Forum Shook Up Stock Market Dynamics
- 5 Top Rated Dividend Stocks to Consider
- Are 2024’s Top Insider Buys a Good Bet for 2025?
- What Is WallStreetBets and What Stocks Are They Targeting?
- 4 Social Media Stocks to Soar as TikTok’s Future Hangs in Balance
Receive News & Ratings for Hemogenyx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemogenyx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
